FDA Issues Warning Letter to Sanofi
January 22, 2025
January 22, 2025
WASHINGTON, Jan. 22 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Sanofi:
* * *
To: Mr. Paul Hudson, Chief Executive Officer, Sanofi, 54, Rue La Boetie, 75008 Paris, France
Dear Mr. Hudson:
The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Genzyme Corporation (a Sanofi subsidiary), FEI 1220423, at 8, 31, 45, 49, 51, 55, 68, 74, 76, 80 . . .
* * *
To: Mr. Paul Hudson, Chief Executive Officer, Sanofi, 54, Rue La Boetie, 75008 Paris, France
Dear Mr. Hudson:
The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Genzyme Corporation (a Sanofi subsidiary), FEI 1220423, at 8, 31, 45, 49, 51, 55, 68, 74, 76, 80 . . .